New Delhi: Zydus Lifesciences Ltd on Friday said it has signed an exclusive agreement with US-based Myriad Genetics to launch a suite of cancer-risk assessment and prognostic diagnostic tests in India, as it looks to expand its precision oncology footprint in the domestic market.
Under the agreement, Zydus will introduce Myriad’s MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus test for ovarian cancer, and Prolaris® Prostate Cancer Prognostic Test for patients, clinicians and healthcare systems across the country. The company will exclusively market and build awareness around these diagnostic platforms in India.
The MyRisk® test is designed to assess hereditary cancer risk through a multigene panel covering 63 clinically significant genes, enabling early risk identification and personalised prevention strategies. Meanwhile, the MyChoice® HRD Plus test helps identify ovarian cancer patients who are more likely to benefit from targeted therapies, while the Prolaris® test supports personalised treatment decisions in prostate cancer by assessing tumour aggressiveness and long-term disease progression.
Commenting on the partnership, Zydus Managing Director Dr Sharvil P. Patel said the collaboration marks a significant step towards expanding access to precision diagnostic tools for cancer care in India, helping clinicians develop personalised treatment plans and improve clinical outcomes for patients.
Myriad Genetics’ Chief Commercial Officer Brian Donnelly said the partnership will help extend precision oncology solutions to India, enabling clinicians to better assess cancer risk, understand tumour biology and guide evidence-based treatment decisions with greater confidence.
Zydus said the tests, which are widely used across North America and Europe, will empower Indian oncologists with advanced genomic decision-support tools at a time when cancer incidence is rising in the country, reinforcing the company’s focus on patient-centric, evidence-based healthcare solutions